Skip to main content
森萱医药 logo

森萱医药 — Investor Relations & Filings

Ticker · 920946 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 417 across all filing types
Latest filing 2025-04-13 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920946

About 森萱医药

https://www.senxuan.cn/

Jiangsu Senxuan Pharmaceutical Co., Ltd. specializes in the research, development, and production of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and specialized fine chemicals. The company’s product portfolio includes key intermediates for antiviral medications, such as those used in the treatment of HIV, and anticonvulsant agents like Primidone. Additionally, it produces high-purity chemical solvents including 1,4-dioxane and 1,3-dioxolane for diverse industrial applications. Senxuan Pharmaceutical maintains a focus on advanced chemical synthesis and large-scale manufacturing capabilities, adhering to international quality standards to support the global life sciences and chemical sectors. Its operations are characterized by a commitment to technical innovation and the supply of critical chemical building blocks for complex therapeutic formulations.

Recent filings

Filing Released Lang Actions
关于拟变更注册地址并修订《公司章程》公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding a proposed change of the company's registered address and corresponding amendments to the company's articles of association. It includes details of the old and new addresses, reasons for the change, and references to board and supervisory committee meeting resolutions. There is no financial data, no mention of annual or interim reports, earnings, or other financial disclosures. The document is a regulatory announcement about corporate governance changes related to the registered address and company bylaws. It is not a full report but a formal announcement of a corporate change. Therefore, it fits best under Regulatory Filings (RNS).
2025-04-13 Chinese
会计师事务所履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is titled '会计师事务所履职情况评估报告' which translates to 'Audit Firm Performance Evaluation Report'. It details the appointment and evaluation of the audit firm (立信会计师事务所) for the 2024 annual audit, including their qualifications, independence, and audit work performed. The content focuses on the audit firm's role and performance rather than presenting the full annual financial report or audit report itself. The document length is 1580 characters, which is relatively short and consistent with an announcement or evaluation rather than a full audit report. There is no detailed financial data or audit results included, only an assessment of the audit firm's performance. Therefore, this document is best classified as an Audit Report / Information (AR) type, which covers standalone audit reports and evaluations of audit firms, excluding full annual reports. FY 2024
2025-04-13 Chinese
董事会审计委员会对会计师事务所履行监督职责情况报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the accounting firm (立信会计师事务所) for the 2024 annual audit. It details the audit firm's qualifications, the audit process, communications with auditors, and the committee's evaluation of the audit firm's performance. It references the 2024 annual financial report audit but does not contain the financial statements or the full audit report itself. The document is a standalone audit-related report focusing on the audit firm's supervision and performance, which fits the definition of an Audit Report / Information (AR). The document length is 2222 characters, which is relatively short but contains substantive audit oversight information rather than just an announcement or certification. Therefore, it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS). FY 2024
2025-04-13 Chinese
2024年度内部控制自我评价报告
Regulatory Filings Classification · 95% confidence The document is titled '2024 年度内部控制自我评价报告' which translates to '2024 Annual Internal Control Self-Evaluation Report'. It is issued by the company's board and discusses the evaluation of the effectiveness of internal controls as of December 31, 2024. The content includes detailed descriptions of internal control systems, evaluation criteria for financial and non-financial control deficiencies, and the conclusion that no major deficiencies were found. The document is comprehensive, contains substantive content about internal control evaluation, and is not merely an announcement or certification. It is not a full annual report (10-K), audit report (AR), or earnings release (ER), but rather a detailed internal control evaluation report. Such reports typically fall under the category of Regulatory Filings (RNS) as they are compliance-related disclosures that do not fit other specific categories. Therefore, the best classification is Regulatory Filings (RNS).
2025-04-13 Chinese
关于使用自有闲置资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Jiangsu Senxuan Pharmaceutical Co., Ltd. regarding the use of its own idle funds for cash management by purchasing short-term financial products. It details the purpose, amount, duration, decision-making process, risk analysis, and impact on the company. The document includes resolutions from the board and supervisory committee meetings and is dated April 14, 2025. The document length is 1588 characters, which is relatively short and reads like a formal announcement rather than a detailed financial report. There are no financial statements or substantive financial data included. The content focuses on informing shareholders and the public about a financing-related decision and the authorization of fund usage, which aligns with a Capital/Financing Update. It is not an annual or interim report, audit report, or earnings release. It is not a report publication announcement since it contains detailed information about the decision itself, not just a notice of report availability. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2025-04-13 Chinese
2024年年度报告摘要
Annual Report Classification · 95% confidence The document is titled as an "年度报告摘要" which translates to "Annual Report Summary" for the year 2024. It contains detailed financial data such as total assets, net profit, earnings per share, and shareholder structure, which are typical components of an annual report. It also includes audit information mentioning a standard unqualified opinion from an accounting firm, which is common in annual reports. The document is about 4959 characters long, which is sufficient to contain substantive financial data and analysis, not just an announcement or summary. Therefore, this document is the actual Annual Report or a substantial part of it, not merely an announcement or a summary without financial details. Hence, the correct classification is Annual Report (10-K). FY 2024
2025-04-13 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.